A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.
In the management of chronic obstructive pulmonary disease (COPD), fewer men than women utilize guideline-recommended, non-pharmacological interventions, such as smoking cessation and physical activity programmes, according to a study. Moreover, active smoking is a risk factor for low uptake.
A once-daily triple therapy of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; ICS/LAMA/LABA*) in a single inhaler significantly reduces the risk of all-cause mortality compared with a dual therapy of UMEC/VI (LAMA/LABA) in chronic obstructive pulmonary disease (COPD) patients with a history of moderate or severe exacerbations, confirm the latest results of the IMPACT** study.
Both antibiotics and systemic corticosteroids reduce treatment failure rates in patients with chronic obstructive pulmonary disease (COPD), regardless of severity of exacerbations, according to a systematic review and meta-analysis of randomized trials.
Use of antibiotics and systemic corticosteroids can help decrease treatment failure in adults with mild-to-severe exacerbation of chronic obstructive pulmonary disease (COPD), results of a systematic review and meta-analysis have shown.
A blood eosinophil value of <0.144 × 109/L on admission or <2 percent is predictive of a longer hospital length of stay (LOS) among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), suggests a study.
Chronic obstructive pulmonary disease (COPD) patients with comorbid chronic cough appear to exhibit a more severe disease in terms of accompanying respiratory symptoms and healthcare utilization, lung function, and inflammation in blood, according to a study.
In chronic obstructive pulmonary disease (COPD) patients initiating inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, both budesonide/formoterol (FOR) dry-powder inhalers and beclomethasone/FOR metered-dose inhalers pose lower risks of severe pneumonia and severe adverse events compared with fluticasone/salmeterol delivered using the same type of inhaler, as reported in a recent study.
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.